Patients may conveniently self-administer the Monarch eTNS system at home and typically use the device while sleeping.
About Trigeminal Nerve Stimulation
The trigeminal nerve is the largest cranial nerve, offering a high-bandwidth pathway for signals to enter the brain, bilaterally and at high frequency. The trigeminal nerve projects directly or indirectly to specific areas of the brain, such as the locus coeruleus, nucleus tractus solitarius, thalamus, and the cerebral cortex, which are involved in epilepsy, depression, attention-deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), and other disorders.
Trigeminal Nerve Stimulation (TNS) is the electrical stimulation of branches of the trigeminal nerve, including those located near the surface of the forehead. Functional neuroimaging data suggests the mechanism of action of TNS is related to its ability to modulate activity in targeted brain regions.
CAUTION: In the United States, the Monarch eTNS System is an investigational device and is limited by Federal law to investigational use.
eTNS, Monarch, and Monarch eTNS are trademarks of NeuroSigma, Inc.
About NeuroSigma, Inc.
NeuroSigma is a California-based life sciences company focused on commercialization of its non-invasive eTNS technology for the treatment of neurological and neuropsychiatric disorders, including epilepsy, depression, PTSD, ADHD, and TBI. The Monarch has received CE mark approval in the European Union as well as regulatory approvals in Canada and Australia.
Back to HCB News
